Rosuvastatin inhibits the smooth muscle cell proliferation by targeting TNFα mediated Rho kinase pathway

Area of Science:

• Cardiovascular Biology
• Molecular Pharmacology
• Cell Signaling

Background:

• Atherosclerosis involves vascular smooth muscle cell (VSMC) proliferation.
• Tumor Necrosis Factor-alpha (TNFα) is implicated in inflammatory processes contributing to atherosclerosis.
• The Rho kinase (ROCK) pathway plays a role in VSMC function.

Purpose of the Study:

• To determine if TNFα activates the Rho kinase pathway, leading to VSMC proliferation.
• To investigate Rosuvastatin's intervention in this process.
• To elucidate Rosuvastatin's anti-atherosclerosis mechanism.

Main Methods:

• Primary Wistar rat VSMC culture.
• Cell proliferation assessed via MTT assay.
• Rho kinase gene expression analyzed by RT-PCR.
• PCNA protein levels measured by Western blot.

Main Results:

• TNFα significantly increased Rho kinase expression and PCNA protein levels in VSMCs (P < 0.05).
• These effects showed positive correlation with treatment duration.
• Rosuvastatin administration inhibited TNFα-induced Rho kinase and PCNA expression (P < 0.05).

Conclusions:

• TNFα-mediated Rho kinase activation promotes VSMC proliferation.
• Rosuvastatin inhibits the Rho kinase pathway and subsequent VSMC proliferation.
• Rosuvastatin demonstrates potential as an anti-atherosclerosis therapeutic by targeting this pathway.